Drug Profile
Research programme: angiogenesis inhibitors - Alchemia
Alternative Names: ACL 16907; Somatostatin agonists - Alchemia; VT 16907Latest Information Update: 29 Aug 2007
Price :
$50
*
At a glance
- Originator Alchemia
- Class
- Mechanism of Action Angiogenesis inhibitors; Somatostatin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Age-related macular degeneration; Cancer; Diabetic retinopathy
Most Recent Events
- 29 Aug 2007 Alchemia has discontinued development of ACL 16907 on commercial grounds
- 04 Sep 2006 Discontinued - Preclinical for Age-related macular degeneration in Australia (unspecified route)
- 07 Aug 2006 Preclinical trials in Age-related macular degeneration in Australia (unspecified route)